Bethanie Wilkinson

Publications by Year

Research Areas

Rheumatoid Arthritis Research and Therapies, Autoimmune and Inflammatory Disorders Research, Systemic Lupus Erythematosus Research, SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies

Most-Cited Works

• → Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine(2020)1,237 cited
• → Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis(2012)931 cited
• → Tofacitinib versus Methotrexate in Rheumatoid Arthritis(2014)765 cited
• → The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo(2009)542 cited
• → Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs(2011)376 cited
• → A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone(2011)344 cited
• → Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans(2001)324 cited
• → The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis(2015)194 cited
• → Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial(2009)147 cited
• → Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis(2009)143 cited